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Abstract: Congenital cardiovascular malformation is a common birth defect incorporating
abnormalities of the outflow tract and aortic arch arteries, and mice deficient in the transcription
factor AP-2α (Tcfap2a) present with complex defects affecting these structures. AP-2α is expressed
in the pharyngeal surface ectoderm and neural crest at mid-embryogenesis in the mouse, but the
precise tissue compartment in which AP-2α is required for cardiovascular development has not been
identified. In this study we describe the fully penetrant AP-2α deficient cardiovascular phenotype
on a C57Bl/6J genetic background and show that this is associated with increased apoptosis in
the pharyngeal ectoderm. Neural crest cell migration into the pharyngeal arches was not affected.
Cre-expressing transgenic mice were used in conjunction with an AP-2α conditional allele to examine
the effect of deleting AP-2α from the pharyngeal surface ectoderm and the neural crest, either
individually or in combination, as well as the second heart field. This, surprisingly, was unable to
fully recapitulate the global AP-2α deficient cardiovascular phenotype. The outflow tract and arch
artery phenotype was, however, recapitulated through early embryonic Cre-mediated recombination.
These findings indicate that AP-2α has a complex influence on cardiovascular development either
being required very early in embryogenesis and/or having a redundant function in many tissue layers.
Keywords: transcription factor AP-2α; cardiovascular development; outflow tract; pharyngeal arch
artery; neural crest cell; pharyngeal ectoderm
1. Introduction
Congenital cardiovascular malformation is a major cause of morbidity and death in childhood,
with an incidence of 1% in live-born infants [1,2]. A significant proportion of these malformations
affect the outflow tract (OFT) and aortic arch arteries, resulting in the mixing of oxygenated and
deoxygenated blood and the inefficient systemic delivery of blood to the body. The mammalian
OFT develops to separate the common trunk exiting the heart into the aorta and pulmonary trunk,
and this process begins at embryonic day (E) 10.5 in the mouse. Cardiac jelly in the OFT is invaded
by neural crest cells (NCC), forming the two major OFT cushions which spiral around each other
with one positioned septally and caudally, and the other parietally and cranially [3]. By E11.5 the
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aortopulmonary septum, which is comprised of second heart field (SHF) cells and NCC [4], protrudes
into the OFT cavity and separates the future aorta and pulmonary trunk vessels by fusing with the
distal ends of the OFT cushions. The proximal intra-pericardial components of the aorta and the
pulmonary trunk are separated from the ventricular outflow tracts by the aortopulmonary septal
complex, comprising of neural crest-derived mesenchyme. After E12.5 the major and intercalated OFT
cushions remodel to form the tricuspid arterial valves and subsequently the aortic root is transferred to
the left ventricle, with the pulmonary trunk remaining as the sole outlet from the right ventricle [3].
The great arteries of the mammalian heart are derived from the pharyngeal arch arteries (PAAs)
which form within the pharyngeal arches. These are temporary embryological structures that develop
as a series of repeated protuberances on either side of the developing pharynx [5]. The pharyngeal
arches consist of paraxial mesoderm- and NCC-derived mesenchyme, enclosed by two epithelial
layers—the pharyngeal ectoderm and endoderm. The PAAs form symmetrically and sequentially
during early embryogenesis in a cranial to caudal sequence and are rapidly remodelled to form the
asymmetric aortic arch arteries seen in the adult [6,7]. The first two pairs of PAAs degenerate early
and contribute to the vascular plexus within the forming jaw, and the third PAAs, on both the right
and the left, form the common carotid arteries. The fourth PAA persists on the right as the proximal
region of the subclavian artery, whilst on the left it contributes to the section of the mature aortic arch
between the origins of the left common carotid artery and the left subclavian artery. The right sixth
PAA regresses, while the left sixth PAA forms the arterial duct. The development of the PAAs appears
to be particularly sensitive to insult during embryonic life, and a variety of teratogens, (e.g., retinoic
acid [8,9]), blood flow perturbations [10,11] and gene mutations in mouse models [12] result in defects
of the cardiovascular system. Additionally, neural crest ablation in the mouse gives rise to a wide
spectrum of OFT and aortic arch patterning defects [13,14]. Moreover, gene interactions within the
pharyngeal epithelia are crucial for PAA development [15–17].
Mice lacking the non-DNA binding transcription factor, Cited2, die in utero with complex
cardiovascular and neural tube malformations [18–21] and CITED2 has been shown to physically
interact with, and co-activate, AP-2α (TFAP2A in humans) [20]. AP-2α, similar to Cited2, is necessary
for cardiovascular and neural tube development [22–24]. Mutations in TFAP2A have been identified
in patients with Peters’ anomaly [25], which frequently has comorbidities with congenital heart
defects [26,27], and cause branchio-oculo-facial syndrome, a disease characterised by a branchial
(or cutaneous) defect, abnormalities of the eyes and a distinct facial phenotype [28]. These patients
may also present with cardiovascular defects, such as atrial septal defect and Tetralogy of Fallot [29,30].
Additionally, TFAP2A has been associated with the negative regulation of the T-box gene, TBX20,
the expression of which is increased in atrial and ventricular biopsies of patients with Tetralogy
of Fallot [31]. Other AP-2 family members have been implicated in congenital heart defects, with
mutations in TFAP2B, causing Char syndrome, where patients present with persistent arterial duct [32],
and decreased TFAP2C levels have been identified in cardiac biopsies of Tetralogy of Fallot patients [31].
In the mouse, AP-2α is expressed in the surface ectoderm and lateral edge of the neural plate at
the 3-somite stage (~E8.0) [33], and in the neural crest cells migrating from the hindbrain region at
the 5-somite stage [34]. By E9.5, AP-2α is expressed in the neural crest derived mesenchyme of the
pharyngeal arches, and the pharyngeal ectoderm, and this expression extends into the mesenchyme
and ectoderm of pharyngeal arches four and six by E10.5 [24]. The cardiovascular defects observed
in AP-2α-null mice affect the OFT (e.g., common arterial trunk) and the aortic arch arteries (e.g.,
interrupted aortic arch) but these present differently depending on the genetic background used [22–24].
Although the OFT and arch artery defects are characteristic of a NCC phenotype [35], published
genetic evidence using Cre-lox techniques suggests that NCC deletion of AP-2α does not result in
cardiovascular malformations although there is perinatal lethality associated with neural tube defects
and cleft palate [36]. This raises important questions as to how cardiovascular defects arise that appear
to be NCC-related, but which have been shown not to be caused by a cell-autonomous NCC phenotype.
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In this study we describe the fully penetrant AP-2α-null cardiovascular phenotype on an enriched
C57Bl/6J genetic background. We also sought to identify the tissue-specific requirement of AP-2α
in cardiovascular development using null and conditional alleles of AP-2α and Cre recombinase
expressing transgenic mice. We demonstrate that an early embryonic deletion of AP-2α is required to
recapitulate the cardiovascular defects seen in the constitutive knockout.
2. Materials and Methods
2.1. Mice
All mice used in this study have been described elsewhere: Tcfap2alacZ-KI (referred to as
AP-2α+/−) [24], a floxed allele of Tcfap2a (referred to as AP-2αflox) [36]; Foxg1Cre [37]; Nkx2-5Cre [38];
Wnt1Cre [39]; Isl1Cre [40]; PGKCre [41]; R26RlacZ [42]; R26Reyfp [43]. All mice used in this study were
backcrossed using a traditional congenic breeding strategy [44] for sufficient generations onto C57Bl/6J
to give an average contribution of >90% C57Bl/6J genomic DNA, and were genotyped by standard
PCR using allele-specific primers (sequences available on request). All studies involving animals were
performed in accordance with the UK Home Office Animals (Scientific Procedures) Act 1986.
2.2. Breeding
Stud male mice were produced by crossing AP-2α+/− with each Cre strain. The AP-2αflox mice
were crossed with R26Reyfp to produce double homozygous females. Male and female mice were mated
and the detection of a vaginal plug the next morning was considered to be embryonic day (E) 0.5.
Pregnant females were culled on the required day and embryos collected. Embryos at E9.5–E11.5 were
staged by somite counting.
2.3. Imaging
The magnetic resonance imaging (MRI) of E15.5 embryos was performed on a 9.4T MR system
and analysed and segmented as described [45]. Following MRI, selected embryos were processed for
standard histology and haematoxylin and eosin staining. Mid-gestation embryos (E10.5 and E11.5)
were analysed by High Resolution Episcopic Microscopy (HREM) as described [46,47]. To create
the 3-dimensional (3D) reconstructions of the heart and arch arteries, MRI and HREM images were
converted into volume datasets and segmented using Amira software (Thermo Fisher Scientific,
Waltham, MA, USA). Structures were manually outlined using the label field function of Amira and
surface rendered to produce the 3D images [45]. X-Gal staining to reveal lacZ activity was performed
using standard procedures. To visualise the patency of pharyngeal arch arteries at E10.5, embryos
were injected with India ink via the left ventricle with pulled Pasteur pipettes.
2.4. Immunohistochemistry
Embryos were embedded in paraffin wax and sectioned. Slides were dewaxed, rehydrated
and immunostained with the following primary antibodies: mouse anti-AP-2α (3B5, Santa Cruz
Biotechnology, Dallas, TX, USA; Catalogue number: sc-12726); rat anti-mouse CD-31 (BD Biosciences,
San Jose, CA, USA; Catalogue number: 550274); chicken anti-GFP (Abcam, Cambridge, UK; Catalogue
number: ab13970); anti-cleaved caspase3 (Cell Signalling Technology, Danvers, MA, USA; Catalogue
number: 9661); anti-phospho-histone H3 (Millipore, Watford, UK; Catalogue number: 06-570). For cell
fate analysis, three embryos for each genotype (n≥ 3 sections per embryo) were assessed and the number
of positively stained cells divided by the total number of cells to give an apoptotic or proliferative
index. NCC were labelled genetically with eYFP using the Wnt1Cre allele, and sections immunostained
with the anti-GFP antibody, and the NCC counted (n = 3 embryos per genotype; n ≥ 3 sections per
embryo). Cell counting was performed using ImageJ software (National Institutes of Health, Bethesda,
MD, USA) using the cell counter feature.
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2.5. RT-PCR
Embryos were collected at E9.5 and the pharyngeal arch region dissected free in ice-cold PBS.
Total RNA was extracted using TRIzol and a PureLink™RNA mini spin column kit, and cDNA synthesis
was carried out using the High Capacity cDNA reverse transcription kit (all from ThermoFisher
Scientific, Waltham, MA, USA). Oligonucleotides were designed to identify the AP-2α wild-type
(5′-TTAAGAAAGGCCCCGTGTCCCTG and 5′-CGTTGGGGTTTACCACGCCAC), floxed and
recombined alleles (5′-TTAAGAAAGGCCCCGTGTCCCTG and 5′-TAACCGCTGCACACACCGCC),
and Gapdh (5′-TGTGCAGTGCCAGCCTCGTC and 5′-TGACCAGGCGCCCAATACGG).
2.6. Western Blotting
Embryos were collected at E10.5, dissected in ice-cold PBS and lysed in 300 µL Laemmli buffer.
Lysates were electrophoresed through a 10% polyacrylamide gel and subsequently transferred to PVDF
membrane. The membrane was blocked in 5% milk solution and incubated with AP-2α antibody,
diluted 1:1000. Secondary antibody was a polyclonal goat anti-mouse HRP (Agilent, Santa Clara, CA,
USA) diluted 1:10,000.
2.7. Statistical Analysis
Cell counts were analysed using a two-tailed unpaired t-test (Prism 8.01 software, GraphPad,
San Diego, CA USA). Fisher’s exact test was used to compare defect frequencies between different
genotypes (SPSS). Groups were considered significantly different when p < 0.05.
3. Results
3.1. Cardiovascular Phenotype in C57Bl/6J AP-2α−/− Embryos
In this study we wanted to identify the tissue in which AP-2α is required to control normal
cardiovascular development. Firstly, however, we analysed the developing cardiovascular system in
embryos deficient for AP-2α (AP-2α−/−) on an enriched C57Bl/6J genetic background using histology,
magnetic resonance imaging (MRI) and high-resolution episcopic microscopy (HREM). AP-2α+/− mice,
which have an IRES-lacZ sequence inserted to disrupt the dimerization and DNA binding domains of
the AP-2α protein [24], were intercrossed and embryos collected at E15.5 for analysis. This revealed
that all AP-2α−/− embryos (n = 10) analysed had a ventricular septal defect (VSD) or an interventricular
communication with an OFT defect (10/10), as shown in Figure 1 and Table 1, with six embryos showing
a double outlet right ventricle, as shown in Figure 1D,E,I,J, two showing an over-riding aorta, as shown
in Figure 1C,H, and two exhibiting transposition of the great arteries (TGA). One embryo with TGA
also had an aberrant right subclavian artery (A-RSA), a right-sided aortic arch and an isolated left
subclavian artery, as shown in Figure 1B,G. Although TGA is a hallmark of heterotaxy [48,49], we did
not observe any other left–right patterning defects in AP-2α−/− embryos. Other aortic arch artery
defects were also observed, including interrupted aortic arch (n = 3/10), as shown in Figure 1H, cervical
origin of the aortic arch (n = 2/10), as shown in Figure 1I, and A-RSA (n = 3/10 retro-oesophageal
and n = 6/10 with a cervical origin), as shown in Figure 1H–J. All AP-2α−/− embryos, except one, also
presented with the previously reported craniofacial and ventral body wall defects [22,23]. One embryo,
with a closed ventral body wall, had less severe craniofacial abnormalities, presenting only with a cleft
palate and abnormal eyes. This embryo displayed a VSD, TGA and A-RSA, as shown in Figure 1O,P,Q.
This suggests that the cardiovascular defects seen in AP-2α−/− embryos are not secondary to the
craniofacial and ventral body wall abnormalities. In comparison to the published data [22,24], the mice
used in this study presented with a significantly increased prevalence of aortic arch artery defects,
as shown in Figure 1R,S. This, therefore, demonstrates that AP-2α−/− embryos on an enriched C57Bl/6J
genetic background have fully penetrant cardiovascular defects affecting the aortic arch arteries, as well
as the OFT.
J. Cardiovasc. Dev. Dis. 2020, 7, 27 5 of 22
J. Cardiovasc. Dev. Dis. 2020, 7, x 5 of 22 
 
demonstrates that AP-2α−/− embryos on an enriched C57Bl/6J genetic background have fully penetrant 
cardiovascular defects affecting the aortic arch arteries, as well as the OFT. 
 
Figure 1. Defects in AP-2α−/− embryos. Images were created from haematoxylin and eosin stained 
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defects including transposition of the great arteries (TGA; B,G,Q), right-sided aortic arch (RAA) and 
arterial duct (R-AD), with an isolated left subclavian artery (I-LSA; B,G), interruption of the aortic 
arch (IAA; H), over-riding aorta (O-Ao; C,H), and cervical origin of the right subclavian artery (cRSA; 
H,I), cervical origin of the aortic arch (c-AoA; I) and double-outlet right ventricle (DORV; D,E,I,J), 
and retro-oesophageal right subclavian artery (A-RSA; E,J,Q). All outflow tract defects were 
associated with a ventricular septal defect (VSD) or an interventricular communication (IVC; C,G–J, 
Q). AP-2α−/− embryos usually also present with severe ventral body wall (M) and craniofacial defects 
(M,N). One AP-2α−/− embryo presented with a mild external phenotype (O) and minor craniofacial 
defects consisting of abnormal eyes (E) and cleft palate (CP; P), although this was accompanied by a 
severe cardiovascular abnormality (Q). (R,S) Effect of genetic background on the AP-2α-null 
cardiovascular phenotype. Data for Black Swiss (BS) and 129/Black Swiss (129/BS) genetic 
backgrounds reproduced from [24]; C57Bl/6J (B6) data from this study (red font). There is a significant 
increase in the number of AP-2α−/− aortic arch artery defects on the B6 background. *** p < 0.005, 
Fisher’s exact test (R). Abbreviations: AD, arterial duct; Ao, aorta; LCC, left common carotid; LSA, 
left subclavian artery; LV, left ventricle; OFT, outflow tract; P, palate; PT, pulmonary trunk; RCC, 
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Figure 1. Defects in AP-2α−/ e bryos. I ages ere created from haematoxylin and eosin stained
transverse sections (A–E) and RI datasets (F–P) from E15.5 embryos. Control AP-2α+/+ embryos
had normal cardiovascular structures (A,F), bodies (K) and palates (L). AP-2α−/− embryos show a
range of defects including transposition of the great arteries (TGA; B,G,Q), right-sided aortic arch
(RAA) and arterial duct (R-AD), with an isolated left subclavian artery (I-LSA; B,G), interruption of
the aortic arch (IAA; H), over-riding aorta (O-Ao; C,H), and cervical origin of the right subclavian
artery (cRSA; H,I), cervical origin of the aortic arch (c-AoA; I) and double-outlet right ventricle (DORV;
D,E,I,J), and retro-oesophageal right subclavian artery (A-RSA; E,J,Q). All outflow tract defects were
associated with a ventricular septal defect (VSD) or an interventricular communication (IVC; C,G–J,Q).
AP-2α−/− embryos usually also present with severe ventral body wall (M) and craniofacial defects (M,N).
One AP-2α−/− embryo presented with a mild external phenotype (O) and minor craniofacial defects
consisting of abnormal eyes (E) and cleft palate (CP; P), although this was accompanied by a severe
cardiovascular abnormality (Q). (R,S) Effect of genetic background on the AP-2α-null cardiovascular
phenotype. Data for Black Swiss (BS) and 129/Black Swiss (129/BS) genetic backgrounds reproduced
from [24]; C57Bl/6J (B6) data from this study (red font). There is a significant increase in the number
of AP-2α−/− aortic arch artery defects on the B6 background. *** p < 0.005, Fisher’s exact test (R).
Abbreviations: AD, arterial duct; Ao, aorta; LCC, left common carotid; LSA, left subclavian artery; LV,
left ventricle; OFT, outflow tract; P, palate; PT, pulmonary trunk; RCC, right common carotid; RSA,
right subclavian artery; RV, right ventricle. Scale, 500 µm.
J. Cardiovasc. Dev. Dis. 2020, 7, 27 6 of 22
Table 1. Cardiovascular defects observed in AP-2α mutant embryos.
Genotype n Abnormal VSD DORV O-Ao TGA
IAA
+/−
A-RSA
cAoA
+/−
A-RSA
RAA
+/−
A-SA
A-RSA
AP-2α−/− 10 10 (100%) 4 6 2 2 a 3 2 1 4
AP-2α−/f;Foxg1Cre 9 0 - - - - - - - -
AP-2α−/f;Nkx2-5Cre 14 2 (14%) 0 0 0 0 0 1 1 0
AP-2α−/f;Wnt1Cre 25 b 3 (12%) 1 0 0 0 0 0 1 1
AP-2α−/f;
Foxg1Cre;Wnt1Cre
6 0 - - - - - - - -
AP-2α−/f;
Nkx2-5Cre;Wnt1Cre
9 1 (11%) 1 0 0 0 0 0 0 1
AP-2α−/f;Isl1Cre 11 4 (36%) c 2 1 0 0 2 0 0 1
AP-2α−/f;PGKCre 10 10 (100%) 1 7 d 0 0 1 4 1 4
a One AP-2α−/− embryo with TGA also had a right-sided arterial duct. b AP-2α−/f;Wnt1Cre embryos from AP-2α and
Wnt1Cre breeding (n = 19) and complex Foxg1Cre;Wnt1Cre breeding (n = 6). c One AP-2α−/f;Isl1Cre embryo also had
a hypoplastic aorta. All OFT defects (i.e., DORV, O-Ao and TGA) were associated with a VSD or an interventricular
communication. d The number of OFT defects in AP-2α−/f;PGKCre embryos (7/10) is not significantly different to
AP-2α−/− embryos (10/10; p = 0.211, Fisher’s exact test). Abbreviations: A-RSA, anomalous right subclavian artery
(i.e., retro-esophageal, cervical or isolated); A-SA; aberrant right or left subclavian (as A-RSA but also includes
isolated left subclavian artery); cAoA, cervical aortic arch; DORV, double outlet right ventricle; IAA, interrupted
aortic arch; O-Ao, overriding aorta; OFT, outflow tract; RAA, right-sided aortic arch; TGA, transposition of the great
arteries; VSD, ventricular septal defect.
As the aortic arch arteries were found to be 100% affected in AP-2α−/− embryos on a C57Bl/6J
genetic background we next examined whether the PAAs forming during E10.5-E11.5 developed
abnormally using HREM (E10.5 to E11.5; 35–47 somites; n = 9) and intracardial ink injection (E10.5;
34–39 somites; n = 10). By HREM, four AP-2α−/− embryos examined at E10.5-E11.0 (35–43 somites),
prior to remodelling of the third and fourth PAAs and the OFT, the fourth pharyngeal arch was
observed to be smaller than in wild-type embryos, as shown in Figure 2B,C. The second PAA was
abnormally persistent in two embryos, the fourth PAAs bilaterally absent or hypoplastic in all four
embryos, and the sixth PAAs not yet formed in two embryos, as shown in Figure 2E,F and Table 2.
By ink injection at E10.5, control embryos (34–42 somites; n = 7) had a symmetrical third, fourth
and sixth PAAs that were patent to ink, and the first and second PAAs had regressed, as shown in
Figure 2G. In AP-2α−/− embryos, 8/10 had a fourth PAA defect where this vessel was either unilaterally
(n = 3/10) or bilaterally (n = 5/10) not patent to ink or hypoplastic in appearance, as shown in Figure 2H,I
and Table 2. Moreover, 4/10 embryos also presented with a unilateral abnormally persisting second
PAA patent to ink, and delayed formation of the sixth PAAs, as shown in Figure 2H,I and Table 2.
At the E11.5 stage in wild-type embryos, the OFT was septated and the right sixth PAA had begun
to regress, although the third and fourth PAAs remained symmetrical, as shown in Figure 2J. Of the
five E11.5 AP-2α−/− embryos examined (45–47 somites), the second PAA was unilaterally persistent
in four embryos and the fourth PAAs were either absent or hypoplastic in four embryos, as shown
in Figure 2K,L and Table 2. The majority of the unilateral second PAA defects in AP-2α−/− embryos
at E10.5-E11.5 affected the right second PAA (in 8/9 cases) whereas the fourth PAAs were affected
bilaterally in 10/19 cases, with the right fourth PAA affected unilaterally in 4/19, and the left in 2/19 cases.
In all AP-2α−/− embryos examined by HREM at E11.5 the OFT remained unseptated and the sixth
PAAs were bilaterally present, as shown in Figure 2K,L.
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Figure 2. Pharyngeal arch artery patterning defects in AP-2α−/− embryos. Images were created from
3-D reconstructions of HREM datasets (A–F, J–L) and from ink injections (G–I). (A,D) Control AP-2α+/+
embryos display normal development of the pharyngeal arches (A) and PAA (D) at E10.5. In AP-2α−/−,
the embryos, the caudal pharyngeal arch can appear hypoplastic (B) or normal (C), and the PAAs are
frequently abnormal showing persistence of the second and absence of the fourth (E) or a hypoplastic
fourth PAA (F). The sixt PAA formation was observed to b delay d in some embry s (E,F). (G–I) Ink
injection shows that the third, four and sixth PAA are symmetrical and patent to ink in c ntrol
embryos (G). In AP-2α−/− embryos the s c nd PAA was paten (H) and he fourth hypoplastic (H,I) or
absent (not shown). (J–L) By E11.5 the outflow tract is septated in control embryos (J). In AP-2α−/−
embryos, the septation of the outflow tract is delayed, and the second PAA is persistent and the
fourth PAA is unilaterally (K) or bilaterally (L) absent. Pharyngeal arches (A–C) and PAAs (D–L) are
numbered. Somite numbers (s) are given. Abbreviations: at, aortic trunk; as, aortic sac; pa, pulmonary
artery; pt, pulmonary trunk. Scale, 100 µm.
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Table 2. Pharyngeal arch artery defects in AP-2α−/− embryos.
Genotype n PAA Abnormal UnilateralDefect
Bilateral
Defect Present Hypo/Int/Absent Absent
AP-2α−/− 19
2 11 (58%) 10 1 1 0 0
4 16 (84%) 6 10 - 8 2
6 11 (58%) 5 6 - 4 2
Embryos were collected and assessed for PAA defects. AP-2α−/− mutants were either injected intracardially with ink
(E10.5; n = 10) or imaged using HREM (E10.5-E11.5; n = 9) to visualise the PAA. Data are combined. For each embryo,
left and right PAA 1–6 was scored as having a unilateral or bilateral defect, and the bilateral defects categorised
as either present, a combination of hypoplastic, interrupted and/or absent (Hypo/Int/Abs), and bilaterally absent.
The first and third PAA were unaffected in all embryos examined. All control AP-2α+/− embryos (n = 9) were normal.
To investigate the endothelial cells lining the developing fourth PAA, we immunostained embryo
sections with anti-PECAM-1 antibody to label endothelial cells. Embryos were collected at the stages
when the fourth PAAa are beginning to form (late E9.5) and have formed (mid E10.5), and five
embryos for each genotype (somite range 26–34) were examined. During E9.5, the fourth pharyngeal
arch becomes apparent, with PECAM-1 stained endothelial cells of the forming fourth PAA visible
close to the dorsal aorta in control (AP-2α+/−) and AP-2α−/− embryos, as shown in Figure 3A–D.
In control embryos with 30 to 34 somites, the fourth pharyngeal arch is well defined with the fourth
PAA displaying a similar diameter to the third PAAs, surrounded by positively stained PECAM-1
endothelium, as shown in Figure 3E,F. However, in AP-2α−/− embryos of an equivalent stage, PECAM-1
positive cells were either clustered and disorganised or had formed a vessel of small diameter, as shown
in Figure 3G,H. It therefore appears that the fourth PAA in the AP-2α−/− embryos are failing to
form correctly.
AP-2α−/− embryos at E15.5 displayed OFT defects, such as double outlet right ventricle, over-riding
aorta and TGA, as shown in Figure 1. We therefore examined the HREM datasets of AP-2α−/− embryos
at E11.5 to see if malrotation of the OFT cushions could explain these phenotypes. During mid-E11.5,
the major septal and parietal cushions are positioned side-by-side, as shown in Figure 4A–C. In AP-2α−/−
embryos, however, the OFT cushions were mal-positioned with the parietal cushion more anterior to
the septal cushion, as shown in Figure 4D–F, reminiscent of the orientation of the cushions at the early
E11.5 stage [16].
These results demonstrate that the cardiovascular phenotype of AP-2α−/− embryos on an enriched
C57Bl/6J genetic background, as assessed by histology, imaging, ink injections and immunostaining,
is caused primarily by the fourth PAA not forming correctly, and aberrant OFT alignment with
the ventricles.
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Figure 3. Pharyngeal arch artery development in AP-2α−/− embryos. Coronal sections were immunostained
with anti-PECAM1 antibody to label endothelial cells of the PAA. (A–D) During the E9.5 stage the fourth
pharyngeal arch is forming but the fourth PAA itself is only beginning to appear in the control and
AP-2α−/− embryos. PECAM1 positive endothelial cells can be seen budding from the dorsal aorta (dAo;
arrows). (E,F) In control embryos at E10.5 the fourth PAAs have formed, have a diameter similar to the
third PAAs, and are lined with PECAM1 positive endothelial cells. (G,H) In AP-2α−/− embryos at E10.5
the third PAAs have formed normally but the fourth PAAs are much smaller and appear more irregular in
shape (arrows). Each PAA is numbered, and somite numbers (s) are given. Scales: (A–G), 100 µm; (A’–G’),
50 µm.
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3.2. Cell Fates in AP-2α−/
NC are important for PA remodel ing [35]. f re i vestigated whether the N C
migrating into the pharyngeal arches were affected in AP-2α− e bryos compared to the controls
using Wnt1Cre and eYFP transgenic mice to linea tr t a d aintain a high percentage of
C57Bl/6J genetic background. Immunostaining as erfor ed for NCC using an anti-GFP antibody,
and cellular apoptosis and proliferation assessed. Embryos were collected at early E10.5 (somite range
32–34), a stage when the fourth PAAs have formed (n = 3 of each genotype). Firstly, apoptosis was
assessed in all the cells within the fourth pharyngeal arch by immunostaining for cleaved caspase-3
activity and a significant two-fold increase in the number of apoptotic cells was identified throughout
the fourth pharyngeal arch in AP-2α−/− embryos compared with control (p = 0.023), as shown in
Figure 5A–C. When NCC, endoderm and ectoderm pharyngeal arch tissue were analysed separately,
we identified a significant 7.7-fold increase in the number of apoptotic cells in the pharyngeal ectoderm
compared to control ectoderm (p = 0.021), as shown in Figure 5C. The levels of apoptosis in the
endoderm and NCC were unchanged compared to the controls. For proliferation, the sections were
immunostained for phosphohistone H3 activity. The levels of proliferation within the fourth pharyngeal
arches of the control and AP-2α−/− embryos were not significantly different, either in total or when
each pharyngeal arch tissue was analysed separately, as shown in Figure 5D–F.
As cell death and proliferation within NCC was unaffected we next investigated whether the
number and density of NCC present in the pharyngeal arches was altered in AP-2α−/− embryos using
lineage traced NCC (n = 3 of each genotype at E10.5). We found no statistically significant difference in
the number or density of NCC within the fourth pharyngeal arches between control and AP-2α−/−
embryos, as shown in Figure 5G,H.
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Figure 5. Increased apoptosis in the pharyngeal ectoder of AP-2 / embryos. Sections from E10.5
control (AP-2α+/−; A, ) and AP-2α / (B,E) embryos were immunostained with cleaved anti-caspase3
(red; A,B), anti-phosphohistone H3 (red; ,E) and anti- FP (green; A,B,D,E) antibodies to detect
apoptosis and proliferating cells within the fourth pharyngeal arch. The number of apoptotic (C) and
proliferating (F) cells were counted and expressed as an index. (G,H), Neural crest cells (NCC) within
the fourth pharyngeal arches of control and AP-2α−/− embryos were counted and expressed as the total
number (G) and the number per 100µm2 (H). Abbreviations: ec/ecto, ectoderm; en/endo, endoderm.
* p < 0.05 (two-tailed unpaired t-test). Somite (s) counts indicated. Scale, 20 µm.
NCC number and density within the pharyngeal arches were, therefore, not affected in AP-2α−/−
embryos, nor was cellular proliferation. Increased levels of apoptosis, however, were observed
in the pharyngeal ectoderm of AP-2α−/− embryos at a critical time of fourth PAA development.
This indicates that the cardiovascular defects observed may be derived from increased apoptosis within
the pharyngeal ectoderm that consequently affects normal development.
3.3. Conditional Deletion of AP-2α from the Pharyngeal Surface Ectoderm
Previous work has demonstrated that, although AP-2α is expressed in NCC, conditional deletion
using neural crest-specific Cre recombinase transgenic mice, Wnt1Cre and P0-Cre, in conjunction with
the AP-2αflox allele, does not result in cardiovascular defects [36]. As apoptosis was significantly
increased in the pharyngeal ectoder , we next exp ored the p ssibility that AP-2α expression in this
tissue may be critical for cardiovascular development, as this is the only other domain in which AP-2α
is expressed during PAA formation, as shown in Figure S1A,B,K. All control embryos analysed with
an AP-2αflox/+;Cre genotype were normal, as shown in Figure 6A–D.
Foxg1Cre is expressed in the pharyngeal ectoderm, endoderm and mesoderm from E8.5, but not
in NCC, as shown in Figure S1C,D [37,50]. Mutant E15.5 embryos conditionally lacking AP-2α from
the pharyngeal ectoderm (AP-2αflox/−;Foxg1Cre) presented with a clefting of the face, and compared
to control embryos, the thymus was not observed in its normal position above the heart, or only
one lobe was seen in this position (n = 7/9), as shown in Figure S2 and Table 3. No cardiovascular
defects, however, were observed, as shown in Table 1. This therefore suggests that conditionally
deleting AP-2α from th pharyngeal surface ectod rm, in combination with endoderm and meso erm,
at least with Foxg1Cr , does not give rise to card ovascular defects. Due to the complex expression
pattern of Foxg1Cre in the head [37], and to mai tain o focus on the cardi v scular ystem, we did
not assess the impact on cr niofacial defects further. As this result was unexpected, we employed a
second Cre transgenic line, Nkx2-5Cre, that has been described to be active in the pharyngeal surface
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ectoderm (and pharyngeal mesoderm and endoderm) from E8.0, but is also not expressed in NCC,
as shown in Figure S1E,F [38,50]. Mutant AP-2αflox/−;Nkx2-5Cre embryos at E15.5 (n = 14) presented
with a craniofacial defect consisting of a midline cleft of the mandible, as shown in Figure 6E,F and
Table 3. The thymus was affected in 5/14 embryos, being either bilaterally or unilaterally absent from
the normal position or reduced in size and split asymmetrically, as shown in Figure 6G and Table 3.
One AP-2αflox/−;Nkx2-5Cre embryo presented with a right-sided aortic arch forming a vascular ring that
looped around the back of the trachea and joined the descending aorta (therefore interrupted on the
left), as shown in Figure 6H and Table 1, and one embryo showed cervical origin of the aortic arch.
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AP-2α conditionally deleted using Isl1Cre showing craniofacial (M,N), thymus absent from its normal 
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Figure 6. Defects following conditional deletion of -2 . ( – ) Control (AP-2α+/flox) embryo with
normal craniofacial appearance (A,B), thymus (C), heart and aortic arch arteries (D). (E–H) Mutant
embryo with AP-2α conditionally deleted using Nkx2-5Cre showing craniofacial (E,F), thymus (G)
and a right-sided aortic arch (RAA) and an aberrant right subclavian artery (A-RSA; H). (I–L) Mutant
embryo with AP-2α conditionally deleted using Wnt1Cre showing exencephaly (I), cleft palate (CP;
J), normal thymus (K), A-RSA and a ventricular septal defect (VSD; L). (M–P) Mutant embryo with
AP-2α conditionally deleted using Isl1Cre showing craniofacial (M,N), thymus absent from its normal
position (asterisk; O), an interrupted aortic arch (IAA) and VSD (P). Abbreviations: AD, arterial duct;
Ao, aorta; LCC, left common carotid; LSA, left subclavian artery; LV, left ventricle; P, palate; RCC, right
common carotid; RSA, right subclavian artery; RV, right ventricle. Scale, 500 µm.
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Table 3. Extra-cardiovascular defects in conditionally deleted AP-2α embryos.
Genotype Thymus Craniofacial
AP-2α−/f;Foxg1Cre
Bilaterally or unilaterally absent
from normal position, reduced in
size and/or split (7/9)
Upper facial cleft (7/9)
AP-2α−/f;Nkx2-5Cre
Bilaterally or unilaterally absent
from normal position, reduced in
size and/or split (5/14)
Midline cleft mandible (14/14)
AP-2α−/f;Wnt1Cre Not affected Cleft palate (5/19);exencephaly (1/19)
AP-2α−/f;
Foxg1Cre;Wnt1Cre
Bilaterally or unilaterally absent
from normal position (6/6)
Upper facial cleft (6/6);
exencephaly (2/6)
AP-2α−/f;
Nkx2-5Cre;Wnt1Cre
Small, split (1/9) Midline cleft mandible (9/9)
AP-2α−/f;Isl1Cre Absent from normal position (9/11)
Midline cleft mandible and upper
facial cleft (8/11); cleft palate (6/11);
exencephaly (1/11)
The selective deletion of AP-2α from the pharyngeal ectoderm using either Foxg1Cre or Nkx2-5Cre
transgenic mice did not, therefore, recapitulate the cardiovascular malformations seen in the global
AP-2α-null embryos.
3.4. Conditional Deletion of AP-2α from the Neural Crest
The possibility that genetic background may have influenced the penetrance of a cardiovascular
phenotype in the previously published work raised the question that perhaps the role of AP-2α in the
neural crest should be re-examined on the inbred C57Bl/6J background. To do this, mice carrying the
Wnt1Cre transgene were used to conditionally delete AP-2α from all NCC [39]. AP-2αflox/−;Wnt1Cre
embryos were examined for cardiovascular defects at E15.5 (n = 19). One embryo presented with
exencephaly, as shown in Figure 6I, five had a cleft palate, as shown in Figure 6J, and the thymus was
unaffected, as shown in Figure 6K and Table 3. Two embryos had cardiovascular defects: one had
a perimembranous VSD with A-RSA, as shown in Figure 6L and Table 1, and one had a vascular
ring, as described above. We therefore identified a very low incidence (10%) of cardiovascular
abnormalities in embryos with a neural crest cell-specific deletion of AP-2α on an enriched C57Bl/6J
genetic background.
3.5. Simultaneous Deletion of AP-2α from the Surface Ectoderm and the Neural Crest
AP-2α is expressed in both NCCs and the pharyngeal surface ectoderm, as shown in Figure S1A,B,K.
As deletion from either tissue individually did not recapitulate the level of cardiovascular defects
seen in the global mutants, we next investigated the possibility that AP-2α is required in both tissues
simultaneously for correct cardiovascular development. We therefore created mutant mice that would
delete AP-2α from the pharyngeal ectoderm and NCC simultaneously. Male mice heterozygous for
AP-2α and transgenic for both Wnt1Cre and Foxg1Cre were crossed to AP-2αflox/flox females, and embryos
collected at E15.5 for analysis. A craniofacial defect was observed in all embryos of the genotype
AP-2αflox/−; Wnt1Cre;Foxg1Cre (n = 6) similar to that seen in Figure S2. In addition, exencephaly was
observed (2/6) as well as thymus defects, as shown in Table 3. By histology, no cardiovascular defects
were observed, although an A-RSA was identified in one AP-2αflox/−;Wnt1Cre embryo from this cohort,
as shown in Table 1. From these data, it appears that the simultaneous deletion of AP-2α from the
NCC and surface ectoderm using Wnt1Cre and Foxg1Cre is unable to cause cardiovascular defects in
mutant embryos. We therefore employed Nkx2-5Cre in conjunction with Wnt1Cre to delete AP-2α from
the surface ectoderm and NCC together. All AP-2αflox/−;Wnt1Cre;Nkx2-5Cre mutant embryos (n = 9)
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showed a facial cleft similar to that shown in Figure 6E,F, and one had a thymus defect, as shown in
Table 3. One AP-2αflox/−;Wnt1Cre;Nkx2-5Cre mutant embryo had a perimembranous VSD and cervical
origin of the right subclavian artery, as shown in Table 1.
In an attempt to delete AP-2α from the pharyngeal ectoderm at a slightly earlier time than with
Nkx2-5Cre and Foxg1Cre, we used Isl1Cre mice [40]. Isl1 is expressed in the SHF as early as E7.0 [51] and
throughout the developing pharyngeal arches in the pharyngeal endoderm, ectoderm and mesoderm,
and in NCC, as shown in Figure S1I,J [43,52,53]. The Isl1Cre transgenic line will therefore delete AP-2α
from the surface ectoderm and NCC component of its expression domain. Mutant AP-2αflox/−;Isl1Cre
embryos (n = 11) at E15.5 were analysed and showed craniofacial and thymus defects, as shown
in Figure 6M–O and Table 3, and four mutants presented with a cardiovascular defect, displaying
perimembranous VSD with either interrupted aortic arch or A-RSA, and a hypoplastic aorta, as shown
in Figure 6P and Table 1.
Taken together, the conditional, and simultaneous deletion, of AP-2α from the pharyngeal
ectoderm and/or NCC, somewhat unexpectedly, did not fully recapitulate the cardiovascular defects
seen in the global AP-2α null embryos. These results indicate that the simultaneous conditional deletion
of AP-2α from the NCC and the surface ectoderm does not result in highly penetrant cardiovascular
malformations, at least not with the Cre lines employed here.
3.6. Early Embryonic Recombination of the AP-2αflox Allele
Because of the unexpected lack of a penetrant cardiovascular phenotype with any of the Cre
lines used in this study, we decided to closely analyse the cardiovascular phenotype produced by a
global deletion of the AP-2αflox allele and compare this to the phenotype seen in the constitutive AP-2α
deficient embryos.
To achieve the recombination of the AP-2αflox allele at an early embryonic stage, we used PGKCre
transgenic mice, which have been reported to express Cre recombinase in all tissues from E3.5 [41].
To confirm that the AP-2αflox allele, as shown in Figure 7A, was being fully recombined we performed
RT-PCR on cDNA made from E10.5 embryo RNA. This demonstrated that the AP-2αflox allele was
correctly recombined in the presence of PGKCre, as shown in Figure 7B. We also showed that no truncated
AP-2α protein was made by Western blotting, as shown in Figure 7C. These data demonstrated that the
AP-2αflox allele was completely recombined and created a null allele. To investigate the cardiovascular
system, stud males of the genotype AP-2α+/−;PGKCre were created, and crossed to AP-2αflox/flox
females to generate mutant (AP-2αflox/−;PGKCre) and control (AP-2αflox/+;PGKCre) embryos at E15.5 for
analysis. The external phenotype clearly recapitulated the AP-2α−/− external phenotype, as shown in
Figure 7G [22–24]. All AP-2αflox/−;PGKCre mutant embryos presented with an aortic arch artery defect
and 70% with an OFT defect, which was not significantly different from the fully penetrant OFT defects
seen in the global AP-2α deficient embryos, as shown in Figure 7H, I and Table 1.
These data indicate that cardiovascular defects equalling the prevalence seen in AP-2α−/− embryos
can only be recapitulated conditionally with an early recombination of the AP-2αflox allele throughout
the embryo in conjunction with the AP-2α null allele.
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tubulin antibody was used as a loading control. (D–F) Control (AP-2α+/flox;PGKCre) embryos were 
externally normal (D) and had a normal heart, outflow tract and aortic arch arteries (E,F). (G–I) 
Conditional deletion of AP-2α using PGKCre (AP-2α−/flox;PGKCre) produced embryos with the typical 
AP-2α-null external phenotype (G) and cardiovascular defects, including interruption of the aortic 
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(DORV) with interventricular communication (IVC; H,I). Abbreviations: AD, arterial duct; Ao, aorta; 
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RCC, right common carotid; RSA, right subclavian artery; RV, right ventricle; Tr, trachea. Scale, 500 
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Figure 7. Defects following global conditional deletion of AP-2α. (A) Cartoon of the AP-2αflox allele [36]
with the functional domains, loxP sites (black triangles) and genotyping primers indicated. (B) RT-PCR
analysis demonstrates that the AP-2αflox allele is fully recombined with PGKCre. (C) No AP-2α protein
is produced following the PGKCre-mediated recombination of the AP-2αflox allele. γ-tubulin antibody
was used as a loading control. (D–F) Control (AP-2α+/flox;PGKCre) embryos were externally normal (D)
and had a normal heart, outflow tract and aortic arch arteries (E,F). (G–I) Conditional deletion of AP-2α
using PGKCre (AP-2α−/flox;PGKCre) produced embryos with the typical AP-2α-null external phenotype
(G) and cardiovascular defects, including interruption of the aortic arch (IAA), cervical origin of
the right subclavian artery (cRSA) and double-outlet right ventricle (DORV) with interventricular
communication (IVC; H,I). Abbreviations: AD, arterial duct; Ao, aorta; dAo, dorsal aorta; LCC, left
common carotid; LSA, left subclavian artery; LV, left ventricle; H, heart; RCC, right common carotid;
RSA, right subclavian artery; RV, right ventricle; Tr, trachea. Scale, 500 µm.
4. Discussion
In this study we have defined the cardiovascular phenotype in mice lacking AP-2α on a C57Bl/6J
genetic background, although we were unable to fully recapitulate the cardiovascular phenotype
seen in AP-2α deficient embryos using a conditional deletion strategy from the neural crest and/or
pharyngeal surface ectoderm. The complete AP-2α deficient phenotype, was, however, achieved
through very early embryonic recombination of the AP-2α conditional allele.
AP-2α is expressed i t NCC and the pharyng al ectoderm of the ph ryng al arc es that
hous the PAAs that will form and remod l to cre te the aortic arch arteries that t ke blo d away
from the heart [2 ,33,34]. C ditional deletion of AP-2α from the NCC and/or the pharyngeal surface
ectoderm, failed to recapitulate the AP-2α-null cardiov scular phenotyp , although a small percentage
dis layed an arch rtery defect. The conditional deletion of AP-2α using Isl1Cre did produce the
highest number of embryos with a cardiovascular malformation (36%) of all the Cre combinations
used. Isl1Cre is expressed throughout the SHF including the pharyngeal epithelia [43,52], but it has
also been reported to be active in the cardiac neural crest [53]. It could therefore be speculated that the
earlier onset of Isl1Cre expression [51], combined with activity in the pharyngeal surface ectoderm
and NCC, could have sufficiently recombined the AP-2αflox allele to produce a limited cardiovascular
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phenotype. The overall timing of the expression of the Cre transgenes used in this study, however,
may therefore be too late to successfully fully recombine the AP-2αflox allele. By employing PGKCre
mutant mice to conditionally delete AP-2α before gastrulation, the full AP-2α-deficient phenotype was
successfully recapitulated. This is analogous to the Cited2 knockout mouse, where the full heterogenous
cardiovascular and laterality phenotype could only be realized conditionally through deletion at
gastrulation [54]. Each Cre line used in this study, however, was able to produce mutant embryos with
craniofacial defects, demonstrating that these lines functioned correctly and were able to recombine
the AP-2αflox allele and impact the formation of these structures later in development. Foxg1Cre,
for example, has a complex expression pattern in the head itself [37], but we have not assessed how
this pattern might cause the observed craniofacial defects, nor with the other Cre strains used in
this study. Nevertheless, the high incidence of craniofacial and thymus defects in the conditional
mutants reflects the efficacy of AP-2α deletion resulting from the Cre transgenes and supports our
conclusions concerning the lack of defects caused by loss of AP-2α in relation to the cardiovascular
system. A recent study has demonstrated that biallelic deletion of AP-2α and AP-2β from NCC results
in more severe craniofacial defects than seen in single NCC mutants [55], indicating that functional
redundancy occurs between these two genes. It is possible, therefore, that cardiovascular development
may also be affected more severely in these mutants, providing an alternative explanation as to why so
few AP-2αflox/−;Wnt1Cre mutant embryos presented with cardiovascular defects here, or not at all in the
earlier report [36]. Recently it has been recognized that the Wnt1Cre line has ectopic overexpression of
Wnt1 in the midbrain, which increases Wnt/ß-catenin signalling, and a new allele has been developed,
Wnt1Cre2, to overcome this issue [56]. This line, however, has been reported to alter NCC-related
phenotypes compared to Wnt1Cre [57]. Although we do not predict that ectopic midbrain Wnt1
overexpression using the Wnt1Cre allele would affect the cardiovascular system in our study, it is
feasible that we may have achieved a different result using the Wnt1Cre2 allele.
Previous studies have described the cardiovascular defects in AP-2α-null embryos and
demonstrated a cardiovascular phenotype consisting of a fully penetrant OFT malformation and a
partially penetrant arch artery phenotype [24]. Here, using mice on an enriched C57Bl/6J genetic
background, we have described the fully penetrant OFT and arch artery defects in AP-2α-null embryos,
demonstrating that AP-2α is critical for the correct development of the cardiovascular system. We did
not, however, find any embryos with a common arterial trunk, as previously reported [24], but did
identify other OFT defects of over-riding aorta and TGA, with the latter not previously described
in AP-2α−/− mutant embryos. This difference in the penetrance of arch artery defects, and the range
in OFT abnormalities observed, may be attributed to the different genetic backgrounds of the mice
used in the various published studies. In our study, all the mice used were calculated to be >90%
C57Bl/6J for each line used, whereas the mice in the previous work were on a Black Swiss [22] or a
mixed genetic background [24]. The AP-2α-null alleles were constructed differently, with the former
using a neomycin cassette to replace exon 6, and the latter having an IRES-lacZ cassette inserted into
exon 7 of the AP-2α gene (also used in this study). Although the presence of a neomycin cassette may
influence neighbouring gene expression that could impact any observed phenotype [58], it is more
likely that the increased penetrance of arch artery defects observed in our study are due to changes in
genetic background that are influencing the presentation of specific phenotypes, as previously shown
for Cited2 and Gbx2, among other genes involved in cardiovascular development [15,21].
The PAA defects observed between E10.5 and E11.5 in AP-2α-null embryos were predominantly
affecting the fourth PAAs, either unilaterally or bilaterally, with the development of this artery
appearing to be arrested between E9.5 and E10.5, as shown by PECAM1 staining. Failure of the
left fourth PAA to form will result in the interruption of the aortic arch and cervical origin of the
aorta, and failure of the right fourth PAA will lead to A-RSA, either retro-oesophageal or with a
cervical origin [59]. The destiny of the persistent second PAA is more difficult to ascertain; it may
regress at a later time in development or may even contribute to the mature aortic arch topology as a
replacement vessel for an absent or aberrantly remodelled one, as is seen in Pax9-null embryos [16].
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Interestingly, the right fourth PAA appeared to be more susceptible to the deletion of AP-2α with 100%
of the constitutive and the conditional mutants by the foetal stage displaying a defect affecting the
right fourth PAA derived vessel (e.g., retro-oesophageal and cervical origin of the right subclavian
artery). Moreover, almost half of the embryos at E10.5–E11.5 had an abnormal right second PAA.
Mouse embryos, heterozygous for Tbx1, present more frequently with A-RSA than interruption of the
aortic arch [16,60], indicating that a right-sided bias does occur in other mouse models of cardiovascular
malformation. Although it has been described that the Tbx1+/− fourth PAA phenotype does partially
recover during development [16,17,61], this does not seem to be the case in AP-2α-deficient mice, as the
incidence of right fourth PAA derived defects is fully penetrant.
AP-2α-null embryos display severe neural tube and ventral body wall closure defects (primary
thoracoabdominoschisis) [22,23] that may occasionally affect the pericardium [24]. Neural tube defects,
such as spina bifida, and foetal thoracoabdominal anomalies, such as gastroschisis and omphalocele,
occur concomitantly with CHD [62–64]. It is therefore possible that the AP-2α-null cardiovascular
phenotype occurs concomitantly, or even secondarily, to the body wall closure defects. This is, however,
unlikely, as we identified one AP-2α-null embryo with an intact ventral body wall and only a mild
craniofacial defect that presented with complex OFT and arch artery defects. Although all AP-2α-null
embryos present with cardiovascular defects incompatible with post-natal life, they are sufficient to
support a circulation in the foetus. Following birth, the closure of the duct would result in the rapid
demise of the neonate and death within 48 h. However, given the severity of the other defects, it is
highly likely that these would independently result in a more immediate post-natal death. For example,
the severe craniofacial, body wall, cranial nerve and skeletal defects would prevent feeding and
breathing [22,23]. By E10.5, AP-2α is no longer expressed in NCCs, but continues to be expressed within
the pharyngeal ectoderm [24]. NCC migration is unaffected in AP-2α-null embryos [23] and we did
not see any defects in NCC apoptosis, proliferation, number or density within the pharyngeal arches,
but did observe a significant increase in the number of apoptotic cells in the fourth pharyngeal arch
ectoderm of AP-2α-null embryos. Increased apoptosis has also been observed in the third and fourth
pharyngeal arch ectoderm of Eya-null embryos [65], and these mice also display complex cardiovascular
defects, such as interruption of the aortic arch and A-RSA that are seen in AP-2α−/− embryos [66].
Interestingly, a role for apoptosis in other tissue compartments has been described in animal models
of cardiovascular developmental defects. Within the pharyngeal mesenchyme of Tgfb2-null mouse
embryos at E11.5, apoptotic cells have been observed surrounding the PAAs just before they begin
to regress [67]. At later stages, aberrant apoptotic cells were located in the fourth PAAs leading to
arch artery defects, such as interrupted aortic arch. Aberrant apoptosis within the tunica media of
the arteries has also been implicated in the development of arch artery defects in diabetic rats [68].
To see if a second wave of apoptosis is contributing to the AP-2α-null cardiovascular phenotype,
the examination of embryos at later stages when the PAA are remodelling (i.e., E11.5–E13.5) would
need to be undertaken. At the stage of development analysed in our study, it is not possible to identify
the apoptotic ectodermal cells beyond that of a monolayer of columnar, polarised epithelial cells, joined
by tight and adherens junctions. The pharyngeal surface ectoderm, however, has been implicated as
an important signalling centre for PAA morphogenesis [17,69], so it is possible that AP-2α expression
in the ectoderm plays a critical role in mammalian PAA development, akin to the role of ectodermal
tfap2a in controlling zebrafish skeletogenesis and the promotion of pharyngeal ectoderm survival [70].
Moreover, for the process of ventral body wall closure during development, AP-2α is required for
signalling from the surface ectoderm to the underlying mesoderm [71]. As NCC are sensitive to
external signals as they migrate [72] we speculate that aberrant signals from the affected pharyngeal
ectoderm may alter their behaviour and ability to properly orchestrate the process of OFT septation
and ventriculo-arterial connections in AP-2α−/− embryos, leading to delayed OFT septation, aberrant
endocardial cushion rotation and subsequently giving rise to the observed OFT defects. Septation does
finally occur in the AP-2α-null embryos as no case of common arterial trunk was observed in our
mutants. The OFT cushions in the AP-2α-null embryos were aberrantly positioned with the parietal
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cushion more caudal to the septal cushion, an organisation seen at an earlier stage in development in
control embryos [16]. The OFT phenotypes observed, therefore, could be attributed to an alteration in
the aortic to pulmonary valve axis angle, following an arrest in normal OFT rotation [73,74]. It should
be noted, however, that the aberrant positioning of the OFT cushions in AP-2α-null embryos may not
represent how the observed defects occur. An alternative mechanism for the correct positioning of the
aorta and pulmonary trunk over the correct ventricles is through an asymmetrical lengthening of the
right ventricular OFT, which causes the pulmonary trunk to be pushed towards its definitive position
in front of the aorta by an asymmetric population of SHF cells [75]. In Lrp2-null mice, for example,
the abnormal migration of this SHF population, along with defective NCC migration, results in common
arterial trunk [76]. Further studies will be required to see if the SHF pulmonary push population has
been affected in AP-2α-null embryos.
5. Conclusions
In this study we have shown that the complex cardiovascular defects in embryos deficient in
AP-2α are fully penetrant on a C57Bl/6J genetic background. Conditional deletion experiments suggest
that AP-2α has a complex influence on cardiovascular development by being required very early in
embryogenesis, having a redundant function in multiple tissue layers, or a combination of both factors.
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